These findings highlight the need for continued development and refinement of standardized HER2 testing methods.
Urothelial Carcinoma
Advertisement
Latest News
Avelumab plus sacituzumab govitecan may improve PFS in patients with advanced bladder cancer.
Although research into urine- and image-based alternatives continues, there is no established replacement for cystoscopy.
The study’s major efficacy outcomes included a complete response in 78% of patients.
The Two Onc Docs weigh IO for BCG-refractory NMIBC, ctDNA monitoring for patients receiving gem/cis for MIBC, and more.
Drs. Necchi and Tawagi break down in detail the first results of SURE-02 in patients with muscle-invasive bladder cancer.
Dr. Faltas highlights CLONEVO, a trial using preoperative abemaciclib in cisplatin-ineligible MIBC with ctDNA monitoring.
Urothelial Carcinoma Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Conference Coverage
Researchers investigated the efficacy of platinum plus 5-FU in the treatment of patients with high-risk penile cancer.
Dr. Attard explores how the study's results compare with prior data in the metastatic castration-resistant setting.
Avelumab plus sacituzumab govitecan may improve PFS in patients with advanced bladder cancer.
At 12 months, the OS rate for patients who received treatment with ipilimumab plus nivolumab was superior to SOC.
The Two Onc Docs review QOL related to doublet ADT with darolutamide, niraparib with abiraterone for mCSPC, and more.
The Two Onc Docs review the 5-year follow-up data on adjuvant pembro and a final analysis on ipi/nivo for metastatic disease.
Advertisement
Advertisement
Trending
Avelumab plus sacituzumab govitecan may improve PFS in patients with advanced bladder cancer.
The study’s major efficacy outcomes included a complete response in 78% of patients.
Drs. Necchi and Tawagi break down in detail the first results of SURE-02 in patients with muscle-invasive bladder cancer.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.